However, some studies did not confirm the significant prognostic role of TAMs in DLBCL patients, as overexpression of CD68 TAMs did not significantly correlate to poorer clinical outcomes [83,84,85]. This evidence concerns the gene CD68 and diffuse large B-cell lymphoma.